46 results on '"Heerspink, Hiddo J.L."'
Search Results
2. Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials
3. Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
4. The Collaborative Nephrology Community: Perspectives and Experience on Data Sharing
5. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
6. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
7. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR
8. Change in Albuminuria and GFR Slope as Joint Surrogate Endpoints for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD
9. The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts
10. Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes
11. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease
12. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes
13. Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria
14. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD
15. A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease
16. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
17. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
18. Endothelin Receptor Antagonists for Kidney Protection
19. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
20. Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D
21. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
22. Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease
23. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
24. Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy: A Post Hoc Analysis from the SONAR Trial
25. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease
26. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease
27. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
28. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
29. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
30. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
31. Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes
32. Discontinuation of RAAS Inhibition in Children with Advanced CKD
33. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%
34. Change in albuminuria as a surrogate endpoint
35. Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation
36. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
37. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis
38. Personalized medicine in diabetic kidney disease
39. ACCORDION: Ensuring That We Hear the Music Clearly
40. Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease
41. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention
42. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
43. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
44. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
45. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
46. Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.